Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00289159
Recruitment Status : Unknown
Verified September 2005 by Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was:  Active, not recruiting
First Posted : February 9, 2006
Last Update Posted : February 9, 2006
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:
Groupe Hospitalier Pitie-Salpetriere

Brief Summary:
To determine wether multimodal MRI (conventinal T1 and T2 sequences, diffusion, magnetization transfer, spectroscopy) is reproducible; to follow up a cohort of patients with early remmittent MS after treatment with interferon.

Condition or disease
Multiple Sclerosis

Layout table for study information
Study Type : Observational
Observational Model: Defined Population
Time Perspective: Prospective
Official Title: Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • MS patients according to Poser's criteria
  • Remitting evolution (less than two years of evolution)
  • Aged 18-50
  • Immunomodulatory treatment indicated

Exclusion Criteria:

  • Unable to perform MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00289159


Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Layout table for investigator information
Principal Investigator: Ayman Tourbah, MD, PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00289159    
Other Study ID Numbers: RBM0110
First Posted: February 9, 2006    Key Record Dates
Last Update Posted: February 9, 2006
Last Verified: September 2005
Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
aged 18-50
remitting evolution
less than two years of evolution
MS patients
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases